Marshall Wace North America L.P. purchased a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 13,756 shares of the biotechnology company’s stock, valued at approximately $674,000. Marshall Wace North America L.P. owned about 0.09% of Anika Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of ANIK. State of Alaska Department of Revenue lifted its stake in shares of Anika Therapeutics by 79.5% during the 2nd quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 1,272 shares during the last quarter. Mason Street Advisors LLC lifted its stake in shares of Anika Therapeutics by 7.1% during the 1st quarter. Mason Street Advisors LLC now owns 3,423 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 228 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Anika Therapeutics by 68.4% during the 1st quarter. Victory Capital Management Inc. now owns 3,452 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 1,402 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in shares of Anika Therapeutics by 3.0% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 100 shares during the last quarter. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Anika Therapeutics during the 1st quarter worth approximately $204,000. 84.47% of the stock is owned by hedge funds and other institutional investors.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 63,799 shares of the company’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the transaction, the chief executive officer now directly owns 174,705 shares in the company, valued at $8,873,266.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Charles H. Sherwood sold 14,201 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total value of $710,476.03. Following the transaction, the chief executive officer now owns 246,740 shares in the company, valued at $12,344,402.20. The disclosure for this sale can be found here. 6.57% of the stock is owned by corporate insiders.

Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 56.01 on Tuesday. The company has a market capitalization of $820.99 million, a price-to-earnings ratio of 24.88 and a beta of 1.65. The company’s 50 day moving average price is $52.21 and its 200-day moving average price is $47.39. Anika Therapeutics Inc. has a 52 week low of $41.38 and a 52 week high of $56.46.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.32. The company had revenue of $33.50 million during the quarter, compared to analyst estimates of $27.20 million. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The firm’s revenue for the quarter was up 25.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.57 earnings per share. Analysts anticipate that Anika Therapeutics Inc. will post $2.20 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the company. Zacks Investment Research raised Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 8th.

WARNING: “Marshall Wace North America L.P. Purchases New Position in Anika Therapeutics Inc. (ANIK)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/marshall-wace-north-america-l-p-purchases-new-position-in-anika-therapeutics-inc-anik/1555914.html.

Anika Therapeutics Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.